AJANTA PHARMA LTD. - 532331 - Results For Second Quarter And Half Year Ended 30Th September 2022
Results for second quarter and half year ended 30th September 202203-11-2022
03-11-2022
AJANTA PHARMA LTD. - 532331 - Corporate Action-Board approves Dividend
Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the record date for taking record of the Members of the Company for the purpose of determination of shareholders to whom interim dividend would be payable would be Monday, 14th November 2022.03-11-2022
AJANTA PHARMA LTD. - 532331 - Board Meeting Outcome for Outcome Of Board Meeting
Pursuant to Regulations 33, 42 & 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that Board of Directors of Company have at their meeting held on 3rd November 2022, approved the following: i. Unaudited Consolidated and Standalone Financial Results of the Company for the second quarter and half year ended 30th September 2022; ii. Payment of interim dividend of Rs. 7/- (350%) per equity share on the face-value of Rs. 2/- per share for the Financial Year 2022-23; iii. Fixed Monday, 14th November 2022 as the Record date for payment of interim dividend. Interim dividend will be paid on or after 24th November 2022.03-11-2022
AJANTA PHARMA LTD. - 532331 - Corporate Action-Board to consider Dividend
This is with reference to our letter dated 21st October 2022, informing you about the Board meeting scheduled on Thursday, 3rd November 2022 to inter-alia consider and take on record the unaudited financial results for the second quarter and half year ended 30th September 2022. Pursuant to Regulation 29(1)(e) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider proposal for: a. declaration of interim dividend, if any, for the financial year ending 31st March 2023; and b. fixation of Monday, 14th November, 2022 as the Record Date for the payment of interim dividend, if declared. You are requested to please take a note of the same and disseminate to all concerned.31-10-2022
AJANTA PHARMA LTD. - 532331 - Update on board meeting
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2022 ,inter alia, to consider and approve This is with reference to our letter dated 21st October 2022, informing you about the Board meeting scheduled on Thursday, 3rd November 2022 to inter-alia consider and take on record the unaudited financial results for the second quarter and half year ended 30th September 2022. Pursuant to Regulation 29(1)(e) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider proposal for: a. declaration of interim dividend, if any, for the financial year ending 31st March 2023; and b. fixation of Monday, 14th November, 2022 as the Record Date for the payment of interim dividend, if declared. You are requested to please take a note of the same and disseminate to all concerned.31-10-2022
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Vide our letter dated 27th October 2022, we had intimated about the Earnings Conference Call scheduled on Thursday, 3rd November 2022. In the attachment thereto, the link for registering for conference call was incorrect. Please find enclosed herewith the Earnings call announcement with correct link.28-10-2022
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 3rd November 2022, post Board meeting.27-10-2022
AJANTA PHARMA LTD. - 532331 - Board Meeting Intimation for Considering And Taking On Record Unaudited Consolidated & Standalone Financial Results For The Second Quarter And Half Year Ended 30Th September 2022
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2022 ,inter alia, to consider and approve unaudited consolidated & standalone Financial Results of the Company for the second quarter and half year ended 30th September 2022.21-10-2022
AJANTA PHARMA LTD. - 532331 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Gaurang ShahDesignation :- Company Secretary and Compliance Officer18-10-2022
AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed a Press Release on 'India's Best Managed Companies' awarded to Ajanta Pharma Ltd. by Deloitte.17-10-2022